[1]
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia : an international journal of headache. 2013 Jul:33(9):629-808. doi: 10.1177/0333102413485658. Epub
[PubMed PMID: 23771276]
[2]
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30:68(5):343-9
[PubMed PMID: 17261680]
[3]
Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, Russell MB, Mitsikostas DD, Jensen RH. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. The journal of headache and pain. 2014 Aug 28:15(1):47. doi: 10.1186/1129-2377-15-47. Epub 2014 Aug 28
[PubMed PMID: 25169882]
Level 3 (low-level) evidence
[4]
Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia : an international journal of headache. 2008 Mar:28(3):226-36. doi: 10.1111/j.1468-2982.2007.01497.x. Epub
[PubMed PMID: 18254893]
[5]
Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain : a journal of neurology. 2003 Jan:126(Pt 1):241-7
[PubMed PMID: 12477710]
[6]
Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurologic clinics. 1990 Nov:8(4):817-28
[PubMed PMID: 1979655]
[7]
Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001 Jul-Aug:41(7):629-37
[PubMed PMID: 11554950]
[8]
Parsons AA. Cortical spreading depression: its role in migraine pathogenesis and possible therapeutic intervention strategies. Current pain and headache reports. 2004 Oct:8(5):410-6
[PubMed PMID: 15361327]
[9]
Fusco M, D'Andrea G, Miccichè F, Stecca A, Bernardini D, Cananzi AL. Neurogenic inflammation in primary headaches. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2003 May:24 Suppl 2():S61-4
[PubMed PMID: 12811594]
[10]
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000 Oct:88(1):41-52. doi: 10.1016/S0304-3959(00)00305-5. Epub
[PubMed PMID: 11098098]
[11]
Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia : an international journal of headache. 1997 Apr:17(2):73-80
[PubMed PMID: 9137841]
[12]
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia : an international journal of headache. 2015 May:35(6):478-88. doi: 10.1177/0333102414547138. Epub 2014 Aug 27
[PubMed PMID: 25164920]
[13]
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000 Jun:40(6):445-50
[PubMed PMID: 10849039]
[14]
Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plastic and reconstructive surgery. 2002 Jun:109(7):2183-9
[PubMed PMID: 12045534]
[15]
Jose A, Nagori SA, Roychoudhury A. Surgical Management of Migraine Headache. The Journal of craniofacial surgery. 2018 Mar:29(2):e106-e108. doi: 10.1097/SCS.0000000000004078. Epub
[PubMed PMID: 29068972]
[16]
Bovim G, Fredriksen TA, Stolt-Nielsen A, Sjaastad O. Neurolysis of the greater occipital nerve in cervicogenic headache. A follow up study. Headache. 1992 Apr:32(4):175-9
[PubMed PMID: 1582835]
[17]
Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalalgia : an international journal of headache. 2014 Apr:34(5):382-91. doi: 10.1177/0333102413512032. Epub 2013 Nov 29
[PubMed PMID: 24293088]
[18]
Reed KL, Black SB, Banta CJ 2nd, Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia : an international journal of headache. 2010 Mar:30(3):260-71. doi: 10.1111/j.1468-2982.2009.01996.x. Epub 2010 Feb 15
[PubMed PMID: 19732075]
[19]
Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, Magis D. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013 Feb 19:80(8):697-704. doi: 10.1212/WNL.0b013e3182825055. Epub 2013 Feb 6
[PubMed PMID: 23390177]
Level 1 (high-level) evidence
[20]
Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia : an international journal of headache. 2005 Feb:25(2):82-6
[PubMed PMID: 15658944]
[21]
Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on migraines. The journal of pain. 2003 Nov:4(9):530-4
[PubMed PMID: 14636821]
[22]
Chen G, You H, Juha H, Lou B, Zhong Y, Lian X, Peng Z, Xu T, Yuan L, Woralux P, Hugo AB, Jianliang C. Trigger areas nerve decompression for refractory chronic migraine. Clinical neurology and neurosurgery. 2021 Jul:206():106699. doi: 10.1016/j.clineuro.2021.106699. Epub 2021 May 20
[PubMed PMID: 34053808]
[23]
Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plastic and reconstructive surgery. 2005 Jan:115(1):1-9
[PubMed PMID: 15622223]
[24]
Totonchi A, Guyuron B, Ansari H. Surgical Options for Migraine: An Overview. Neurology India. 2021 Mar-Apr:69(Supplement):S105-S109. doi: 10.4103/0028-3886.315999. Epub
[PubMed PMID: 34003155]
Level 3 (low-level) evidence
[25]
Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Transactions of the American Ophthalmological Society. 1981:79():734-70
[PubMed PMID: 7043872]
[26]
Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999 Nov 10:53(8):1850-3
[PubMed PMID: 10563638]
[27]
Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clinical & experimental ophthalmology. 2014 Apr:42(3):254-61. doi: 10.1111/ceo.12165. Epub 2013 Aug 4
[PubMed PMID: 23844601]
[28]
Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism & related disorders. 2008:14(5):407-14. doi: 10.1016/j.parkreldis.2007.11.003. Epub 2008 Mar 5
[PubMed PMID: 18325821]
Level 1 (high-level) evidence
[29]
Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (London, England). 1986 Aug 2:2(8501):245-7
[PubMed PMID: 2874278]
Level 1 (high-level) evidence
[30]
Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990 Aug:40(8):1213-8
[PubMed PMID: 2199847]
Level 1 (high-level) evidence
[31]
Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. Journal of neurology, neurosurgery, and psychiatry. 1990 Aug:53(8):633-9
[PubMed PMID: 2213039]
[32]
Brin MF, Blitzer A, Fahn S, Gould W, Lovelace RE. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Movement disorders : official journal of the Movement Disorder Society. 1989:4(4):287-96
[PubMed PMID: 2811888]
[33]
Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Movement disorders : official journal of the Movement Disorder Society. 1987:2(4):237-54
[PubMed PMID: 3504553]
[34]
Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Movement disorders : official journal of the Movement Disorder Society. 2011 Mar:26(4):750-3. doi: 10.1002/mds.23504. Epub 2011 Feb 1
[PubMed PMID: 21506157]
[35]
Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. The British journal of dermatology. 1997 Apr:136(4):548-52
[PubMed PMID: 9155956]
Level 1 (high-level) evidence
[36]
Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 Jan:44(1):35-42; discussion 42-3
[PubMed PMID: 14979881]
[37]
Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2000 Dec:123(6):669-76
[PubMed PMID: 11112955]
[38]
Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008 Feb:48(2):201-9
[PubMed PMID: 18042229]
[39]
Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia : an international journal of headache. 2004 Oct:24(10):838-43
[PubMed PMID: 15377314]
Level 1 (high-level) evidence
[40]
Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007 Apr:47(4):486-99
[PubMed PMID: 17445098]
Level 1 (high-level) evidence
[41]
Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal of the American Academy of Dermatology. 2005 Sep:53(3):407-15
[PubMed PMID: 16112345]
Level 3 (low-level) evidence
[42]
Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression. Plastic and reconstructive surgery. 2011 Jul:128(1):123-131. doi: 10.1097/PRS.0b013e3182173d64. Epub
[PubMed PMID: 21701329]
Level 1 (high-level) evidence
[43]
Guyuron B, Varghai A, Michelow BJ, Thomas T, Davis J. Corrugator supercilii muscle resection and migraine headaches. Plastic and reconstructive surgery. 2000 Aug:106(2):429-34; discussion 435-7
[PubMed PMID: 10946944]
[44]
Popeney CA, Aló KM. Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache. 2003 Apr:43(4):369-75
[PubMed PMID: 12656708]
[45]
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia : an international journal of headache. 2011 Feb:31(3):271-85. doi: 10.1177/0333102410381142. Epub 2010 Sep 22
[PubMed PMID: 20861241]
Level 2 (mid-level) evidence
[46]
Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisman J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia : an international journal of headache. 2012 Dec:32(16):1165-79. doi: 10.1177/0333102412462642. Epub 2012 Oct 3
[PubMed PMID: 23034698]
Level 1 (high-level) evidence
[47]
Mueller OM, Gaul C, Katsarava Z, Diener HC, Sure U, Gasser T. Occipital nerve stimulation for the treatment of chronic cluster headache - lessons learned from 18 months experience. Central European neurosurgery. 2011 May:72(2):84-9. doi: 10.1055/s-0030-1270476. Epub 2011 Mar 29
[PubMed PMID: 21448856]